Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

256 articles about Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

• New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination With External Radiation

  10/30/2017

  Investigators observed that CLR 127 was taken up and retained in the tumor cells at 6-10 fold higher level than normal tissue and sensitized the tumor cells to external radiation.

• Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma

  10/24/2017

  In September, the trial's Data Monitoring Committee (DMC) determined that the fourth cohort single dose of 31.25 mCi/m2 was safe and tolerated.

• Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors

  10/17/2017

  The Japanese Patent Office has granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125.

• Cellectar Biosciences Announces Successful Completion Of $7.76 Million Registered Direct Offering

  10/12/2017

• Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market

  10/11/2017

• Cellectar Biosciences And Pierre Fabre Extend Collaboration For Development Of New Phospholipid Drug Conjugates

  10/10/2017

• Cellectar Biosciences Reports Cohort Four Data And Partial Response In Relapsed Or Refractory Multiple Myeloma Patient Treated With CLR 131

  9/27/2017

• Cellectar Biosciences Enters Into Strategic Collaboration With Onconova To Develop New Phospholipid Drug Conjugates

  9/21/2017

• Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer

  9/18/2017

• Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential To Improve Therapeutic Window

  8/22/2017

• Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance

  8/15/2017

• Cellectar Biosciences ’ CLR 131 Achieves Overall Survival Of Greater Than 22 Months In Advanced Multiple Myeloma Patients

  8/8/2017

• Cellectar Biosciences To Host Conference Call On August 14, 2017 To Report Second Quarter 2017 Financial Results And Corporate Performance

  8/3/2017

• Cellectar Biosciences Signs Collaboration With Avicenna Oncology To Develop New PDCs For Solid Tumors

  8/1/2017

• Three Abstracts On Dosing Regimens Of Cellectar Biosciences ’s CLR 131 In A Variety Of Tumor Types Published In The 2017 ASCO Annual Meeting Proceedings

  5/18/2017

• Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance

  5/12/2017

• Cellectar Biosciences To Host Conference Call On May 11, 2017 To Report First Quarter 2017 Financial Results And Corporate Performance

  5/2/2017

• Cellectar Biosciences ’s Radiotherapeutic Pdcs Demonstrate An Increased Survival Benefit Using Multiple Doses In Preclinical Studies

  4/27/2017

• Cellectar Biosciences Receives Additional U.S. Patents For PDC Optical Agents In The Detection Of Multiple Cancers

  4/25/2017

• Cellectar Biosciences Receives Japanese Patent For CLR 131 And CLR 125 For The Treatment Of Cancer Stem Cells

  4/18/2017